Crohn's Disease Clinical Trials

Showing 81-100 of 1,088 trials

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT07123350

The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and March 31, 2025, as part of normal patient care, will be retrospectively reviewed and analyzed.

Inflammatory Bowel Disease (IBD)Crohn&Amp;#39;s Disease (CD)Ulcerative Colitis (UC)

Vanderbilt University Medical Center120 participantsStarted Oct 2025

Nashville, Tennessee, United States

RECRUITING

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555

The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.

Crohn's Disease

Alimentiv Inc.300 participantsStarted Mar 2024

Sun City, Arizona, United States • Kissimmee, Florida, United States • Evanston, Illinois, United States +22 more locations

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Related Searches

A Pilot Study on the Efficacy and Safety of a Novel Synbiotic Formula (SGR11) in Patients With Inflammatory Bowel Disease (IBD)

Impact of a Structured Therapeutic Education Session on the Practice of Adapted Physical Activity in Chronic Inflammatory Bowel Diseases

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Comparison of the Therapeutic Effects of Balloon Assisted Enteroscopy Assisted Narrow Incision and Balloon Dilation in the Treatment of Crohn's Disease Small Intestinal Stenosis

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults

Pregnancy and Inflammatory Bowel Disease

Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients

Low Dose IL-2 for the Treatment of Crohn's Disease

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

Analysis of Barriers and Facilitators to Adapted Physical Activity for Pediatric Patients With Chronic Inflammatory Bowel Diseases

Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease

Expanded Access to Upadacitinib

Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility

Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)

OptiMized REsistaNt Starch in Inflammatory Bowel Disease: The MEND Trial